Merck & Co.'s Transitional Year Is Off To A Sluggish Start
The company, in the midst of a leadership and structural transition, said the pandemic negatively impacted revenues by about $600m.
You may also be interested in...
Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Merck & Co.'s CFO Robert Davis will succeed Ken Frazier as CEO. Frazier was one of the architects of the Schering-Plough acquisition, which shaped the pharma for the next decade and delivered its top-selling drug, Keytruda.